Infectious Diseases

  • 4 June 2019
    News

    Merck secures FDA expanded indication for Zerbaxa

    The US Food and Drug Administration (FDA) has approved Merck’s antibiotic Zerbaxa to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and above.

Close
Close
Close

Go Top